NSCLC (Issue 11) | Special Reports

Erlotinib Plus Bevacizumab in EGFR-Mutant NSCLC

November 18, 2016

Clinical Articles

Howard L. “Jack” West, MD, thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the combination of erlotinib plus bevacizumab (Avastin) as a frontline treatment for patients with unresectable advanced, metastatic, or recurrent EGFR-mutant non-small cell lung cancer (NSCLC).

Clinical Trials Exploring Bevacizumab in NSCLC

November 17, 2016

Clinical Articles

Catherine Shu, MD, medical oncologist, Division of Hematology/Oncology, Columbia University Medical Center, discusses two clinical trials exploring the use of bevacizumab (Avastin) in patients with non-small cell lung cancer.

Expert Explores Treatments for Biomarker-Negative Lung Cancer

November 17, 2016

Clinical Articles

The majority of patients with non–small cell lung cancer do not harbor an actionable marker, calling for future research into optimal therapies and combinations for patients with non-driver adenocarcinoma.

Erlotinib/Bevacizumab Combo Warrants Consideration for EGFR+ NSCLC

November 17, 2016

Clinical Articles

The promising clinical efficacy seen with the combination of erlotinib and bevacizumab as a treatment for patients with EGFR-mutant non–small cell lung cancer warrants widespread consideration.

Pathological Response Following Neoadjuvant Triplet Associated With Recurrence-Free Survival

November 15, 2016

Clinical Articles

The pathological response following pre-operative cisplatin, pemetrexed, and bevacizumab treatment may serve as a surrogate marker for post-surgical recurrence-free survival in patients with non-squamous non–small cell lung cancer.

Addressing the Challenges of Treating Non-Driver NSCLC

November 15, 2016

Clinical Articles

Targeted therapies have revolutionized the treatment of patients with non–small cell lung cancer; however, not all patients harbor identifiable driver mutations. Standard treatment options among patients lacking molecular targets include chemotherapy and antiangiogenesis agents.